Motif Bio PLC is a UK-based biopharmaceutical company. Its business is to develop antibiotics for the treatment of infections caused by multi-drug resistant bacteria. The company's key product is the Iclaprim, which addresses bacterial infections, such as acute bacterial skin and skin structure infections and hospital-acquired bacterial pneumonia. Iclaprim exhibits potent activity against Gram-positive clinical isolates of various genera of staphylococci. Motif Bio generates revenue from the sale of its pharmaceutical products mainly in the United Kingdom.Motif Bio PLC is a United Kingdom-based pharmaceutical products manufacturer. It is mainly focused on the development of antibiotic drugs to fight bacterial infections such as acute bacterial skin and skin structure infections.